Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals

RXRXBullishFDA Approvalnews

High materiality8/10

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 9:04 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

FDA approval and market potential are positive signals, similar to previous successful drug launches.

AI summary

What happened, with direct paths to the underlying reporting

Recursion's drug REC-1245 received FDA approval for a clinical trial. Potential market includes over 100,000 patients in the U.S. and EU. Phase 1 trial safety data expected by late 2024. Company plans to merge with Exscientia to enhance data capabilities. Stock is currently down 38% in 2024, 60% below its 52-week high.

Recursion's drug REC-1245 received FDA approval for a clinical trial.
Potential market includes over 100,000 patients in the U.S. and EU.
Phase 1 trial safety data expected by late 2024.
Company plans to merge with Exscientia to enhance data capabilities.
Stock is currently down 38% in 2024, 60% below its 52-week high.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Recursion Pharmaceuticals Reports Strong Clinical Progress and Secure Cash Position

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn